Study Evaluating the Efficacy and Safety of Etanercept
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of etanercept 25 mg administered subcutaneously twice-weekly for 12
weeks in patients with active RA for whom classical antirheumatic therapy is insufficient or
inappropriate.